Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Thursday

Werewolf Therapeutics (NASDAQ:HOWL) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:00 PM ET.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. On average, analysts expect Werewolf Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Werewolf Therapeutics Price Performance

HOWL opened at $1.31 on Tuesday. The stock has a 50-day moving average price of $1.62 and a 200-day moving average price of $1.32. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30. The firm has a market cap of $59.91 million, a PE ratio of -0.80 and a beta of 0.73. Werewolf Therapeutics has a 1 year low of $0.60 and a 1 year high of $2.52.

Analyst Ratings Changes

A number of equities research analysts have issued reports on HOWL shares. JMP Securities cut their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Bank of America decreased their price target on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. Finally, Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Insider Transactions at Werewolf Therapeutics

In related news, major shareholder Ansbert Gadicke sold 94,063 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $1.29, for a total transaction of $121,341.27. Following the completion of the transaction, the insider directly owned 6,147,610 shares of the company’s stock, valued at $7,930,416.90. The trade was a 1.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Bioventures 2014 L.P. Mpm sold 94,063 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $1.29, for a total value of $121,341.27. Following the sale, the insider directly owned 6,147,610 shares in the company, valued at $7,930,416.90. This trade represents a 1.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,508,621 shares of company stock valued at $2,213,924 over the last ninety days. Insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Jane Street Group LLC bought a new stake in Werewolf Therapeutics in the second quarter valued at about $409,000. Marshall Wace LLP acquired a new position in Werewolf Therapeutics in the second quarter valued at approximately $113,000. Bridgeway Capital Management LLC boosted its position in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the period. Finally, AQR Capital Management LLC acquired a new position in Werewolf Therapeutics during the 1st quarter worth $79,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.